S&P 500   4,553.28 (-0.52%)
DOW   34,589.63 (-0.14%)
QQQ   385.24 (-1.20%)
AAPL   161.97 (-1.09%)
MSFT   325.18 (-1.31%)
FB   303.85 (-2.11%)
GOOGL   2,849.63 (-0.34%)
AMZN   3,402.30 (-1.02%)
TSLA   1,044.20 (-3.72%)
NVDA   308.75 (-3.89%)
BABA   109.49 (-10.25%)
NIO   32.62 (-9.89%)
CGC   9.83 (-5.12%)
AMD   144.55 (-4.07%)
GE   93.76 (-1.54%)
MU   82.05 (-1.00%)
T   23.01 (-0.17%)
F   19.52 (-1.76%)
DIS   145.03 (-1.47%)
PFE   53.18 (+0.26%)
AMC   28.42 (-6.14%)
ACB   5.91 (-3.75%)
BA   196.46 (-2.93%)
S&P 500   4,553.28 (-0.52%)
DOW   34,589.63 (-0.14%)
QQQ   385.24 (-1.20%)
AAPL   161.97 (-1.09%)
MSFT   325.18 (-1.31%)
FB   303.85 (-2.11%)
GOOGL   2,849.63 (-0.34%)
AMZN   3,402.30 (-1.02%)
TSLA   1,044.20 (-3.72%)
NVDA   308.75 (-3.89%)
BABA   109.49 (-10.25%)
NIO   32.62 (-9.89%)
CGC   9.83 (-5.12%)
AMD   144.55 (-4.07%)
GE   93.76 (-1.54%)
MU   82.05 (-1.00%)
T   23.01 (-0.17%)
F   19.52 (-1.76%)
DIS   145.03 (-1.47%)
PFE   53.18 (+0.26%)
AMC   28.42 (-6.14%)
ACB   5.91 (-3.75%)
BA   196.46 (-2.93%)
S&P 500   4,553.28 (-0.52%)
DOW   34,589.63 (-0.14%)
QQQ   385.24 (-1.20%)
AAPL   161.97 (-1.09%)
MSFT   325.18 (-1.31%)
FB   303.85 (-2.11%)
GOOGL   2,849.63 (-0.34%)
AMZN   3,402.30 (-1.02%)
TSLA   1,044.20 (-3.72%)
NVDA   308.75 (-3.89%)
BABA   109.49 (-10.25%)
NIO   32.62 (-9.89%)
CGC   9.83 (-5.12%)
AMD   144.55 (-4.07%)
GE   93.76 (-1.54%)
MU   82.05 (-1.00%)
T   23.01 (-0.17%)
F   19.52 (-1.76%)
DIS   145.03 (-1.47%)
PFE   53.18 (+0.26%)
AMC   28.42 (-6.14%)
ACB   5.91 (-3.75%)
BA   196.46 (-2.93%)
S&P 500   4,553.28 (-0.52%)
DOW   34,589.63 (-0.14%)
QQQ   385.24 (-1.20%)
AAPL   161.97 (-1.09%)
MSFT   325.18 (-1.31%)
FB   303.85 (-2.11%)
GOOGL   2,849.63 (-0.34%)
AMZN   3,402.30 (-1.02%)
TSLA   1,044.20 (-3.72%)
NVDA   308.75 (-3.89%)
BABA   109.49 (-10.25%)
NIO   32.62 (-9.89%)
CGC   9.83 (-5.12%)
AMD   144.55 (-4.07%)
GE   93.76 (-1.54%)
MU   82.05 (-1.00%)
T   23.01 (-0.17%)
F   19.52 (-1.76%)
DIS   145.03 (-1.47%)
PFE   53.18 (+0.26%)
AMC   28.42 (-6.14%)
ACB   5.91 (-3.75%)
BA   196.46 (-2.93%)
NASDAQ:NRBO

NeuroBo Pharmaceuticals Stock Forecast, Price & News

$1.45
-0.04 (-2.68%)
(As of 12/3/2021 10:04 AM ET)
Add
Compare
Today's Range
$1.45
$1.46
50-Day Range
$1.49
$4.06
52-Week Range
$1.44
$7.61
Volume
165 shs
Average Volume
983,141 shs
Market Capitalization
$38.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.4
30 days | 90 days | 365 days | Advanced Chart
Receive NRBO News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroBo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


NeuroBo Pharmaceuticals logo

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline include ANA001, a proprietary oral niclosamide formulation; Gemcabene, which is assessed as an acute indication for COVID-19; NB-01, a treatment for painful diabetic neuropathy; and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Boston, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NRBO
Employees
7
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.37 per share

Profitability

Net Income
$-29.68 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
12,123,000
Market Cap
$38.56 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
4/21/2022

MarketRank

Overall MarketRank

2.19 out of 5 stars

Medical Sector

401st out of 1,391 stocks

Pharmaceutical Preparations Industry

178th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












NeuroBo Pharmaceuticals (NASDAQ:NRBO) Frequently Asked Questions

Is NeuroBo Pharmaceuticals a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuroBo Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NeuroBo Pharmaceuticals stock.
View analyst ratings for NeuroBo Pharmaceuticals
or view top-rated stocks.

How has NeuroBo Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

NeuroBo Pharmaceuticals' stock was trading at $12.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NRBO shares have decreased by 88.4% and is now trading at $1.45.
View which stocks have been most impacted by COVID-19
.

Are investors shorting NeuroBo Pharmaceuticals?

NeuroBo Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totaling 47,800 shares, a decrease of 53.9% from the October 31st total of 103,600 shares. Based on an average trading volume of 526,200 shares, the short-interest ratio is presently 0.1 days. Currently, 0.4% of the company's stock are sold short.
View NeuroBo Pharmaceuticals' Short Interest
.

When is NeuroBo Pharmaceuticals' next earnings date?

NeuroBo Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, April 21st 2022.
View our earnings forecast for NeuroBo Pharmaceuticals
.

How were NeuroBo Pharmaceuticals' earnings last quarter?

NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.02.
View NeuroBo Pharmaceuticals' earnings history
.

What price target have analysts set for NRBO?

1 Wall Street analysts have issued 1-year price objectives for NeuroBo Pharmaceuticals' shares. Their forecasts range from $16.00 to $16.00. On average, they anticipate NeuroBo Pharmaceuticals' stock price to reach $16.00 in the next twelve months. This suggests a possible upside of 1,003.4% from the stock's current price.
View analysts' price targets for NeuroBo Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are NeuroBo Pharmaceuticals' key executives?

NeuroBo Pharmaceuticals' management team includes the following people:
  • Jeong Gu Kang, President, CEO, CFO, Secretary & Treasurer
  • Ben Gil Price, Chief Medical Officer

What other stocks do shareholders of NeuroBo Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroBo Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Cumberland Pharmaceuticals (CPIX), Akero Therapeutics (AKRO), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), CorMedix (CRMD), Trevena (TRVN), VBI Vaccines (VBIV), VIVUS (VVUS) and Aldeyra Therapeutics (ALDX).

What is NeuroBo Pharmaceuticals' stock symbol?

NeuroBo Pharmaceuticals trades on the NASDAQ under the ticker symbol "NRBO."

Who are NeuroBo Pharmaceuticals' major shareholders?

NeuroBo Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.27%), BlackRock Inc. (0.20%) and Citadel Advisors LLC (0.00%).

Which major investors are selling NeuroBo Pharmaceuticals stock?

NRBO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc..

Which major investors are buying NeuroBo Pharmaceuticals stock?

NRBO stock was acquired by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, and Geode Capital Management LLC.

How do I buy shares of NeuroBo Pharmaceuticals?

Shares of NRBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeuroBo Pharmaceuticals' stock price today?

One share of NRBO stock can currently be purchased for approximately $1.45.

How much money does NeuroBo Pharmaceuticals make?

NeuroBo Pharmaceuticals has a market capitalization of $38.56 million. The company earns $-29.68 million in net income (profit) each year or ($1.72) on an earnings per share basis.

How many employees does NeuroBo Pharmaceuticals have?

NeuroBo Pharmaceuticals employs 7 workers across the globe.

What is NeuroBo Pharmaceuticals' official website?

The official website for NeuroBo Pharmaceuticals is www.neurobopharma.com.

Where are NeuroBo Pharmaceuticals' headquarters?

NeuroBo Pharmaceuticals is headquartered at 200 Berkeley Street Office 19th Floor, Boston MA, 02116.

How can I contact NeuroBo Pharmaceuticals?

NeuroBo Pharmaceuticals' mailing address is 200 Berkeley Street Office 19th Floor, Boston MA, 02116. The company can be reached via phone at (857) 702-9600, via email at [email protected], or via fax at 734-293-0444.


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.